Concepedia

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events

Zhaoliang Huang, Xinghua Pang, Tingting Zhong, Tailong Qu, Na Chen, Ma Shun, Xinrong He, Dennis Xia, Max Wang, Michelle Xia,

Frontiers in Immunology · 2022 · 37 citations · 35 references

DOIFull text

Open access

Abstract

www.ClinicalTrials.gov, identifier: AK105-101: NCT03352531, AK105-201: NCT03722147, AK105-301: NCT03866980, AK105-202:NCT03866967, AK105-203: NCT04172571, AK105-204: NCT04172506.

References

35

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.5K citations · Full text

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Christopher Garris, Sean P. Arlauckas, Rainer H. Köhler et al. · Immunity · 2018 · 899 citations · Full text

, , +12

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, Soonmo Peter Kang, Drew Rasco et al. · Clinical Cancer Research · 2015 · 767 citations

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

Kaoru Abiko, Noriomi Matsumura, Junzo Hamanishi et al. · British Journal of Cancer · 2015 · 689 citations · Full text